ArticleJournal of gynecologic oncology2019

Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.

Yong Man Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.